Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma Clear all
Completed No phase listed Observational

Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients

NCT05654493
View directory record Official record
Conditions
Glaucoma
Interventions
MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 7, 2026, 9:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Performance on Virtual Reality Visual Field Devices as Compared to Standard of Care

NCT04994457
View directory record Official record
Conditions
Glaucoma
Interventions
Virtual Reality Visual Field, Standard Automated Perimetry
Device · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 90 Years
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Jun 7, 2026, 9:20 AM EDT
Withdrawn No phase listed Observational

24-hour IOP Fluctuation Profile Recorded With SENSIMED Triggerfish in Primary Open-angle Glaucoma (POAG) Patients After Cataract Surgery

NCT01495299
View directory record Official record
Conditions
Glaucoma
Interventions
Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Not applicable Interventional

Improving African American Glaucoma Patient Involvement in Visits and Outcomes

NCT03657147
View directory record Official record
Conditions
Glaucoma
Interventions
Educational Video and Question Prompt List
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

Hydrus Microstent for Refractory Open-Angle Glaucoma

NCT03267134
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 7, 2026, 9:20 AM EDT
Enrolling by invitation No phase listed Observational

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT05506423
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis System
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04285580
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, LUMIGAN
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

NCT00652496
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Wenatchee, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Jun 7, 2026, 9:20 AM EDT
Recruiting Not applicable Interventional

The Glaucoma and Retinopathy Screening Study

NCT06882356
View directory record Official record
Conditions
Glaucoma
Interventions
AI-based glaucoma screening, IOP measurement, Virtual Reality Visual Field Testing
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Chelsea, Massachusetts • Lynn, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jun 7, 2026, 9:20 AM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

NCT06848946
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
Interventions
iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery
Combination Product · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
45 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kenosha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 7, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Comparison of Latanoprost Vs. Timolol

NCT00579969
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

NCT00705757
View directory record Official record
Conditions
Glaucoma, Application Site Pigmentation Changes
Interventions
latanoprost, bimatoprost, travoprost
Drug
Lead sponsor
Summa Health System
Other
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Arlington Heights, Illinois • Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jun 7, 2026, 9:20 AM EDT
Enrolling by invitation Not applicable Interventional

Electrical Stimulation of the Optic Nerve in Patients With Glaucoma.

NCT06693882
View directory record Official record
Conditions
Glaucoma
Interventions
EYETRONIC Nextwave System
Device
Lead sponsor
Glaucoma Center of San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Jun 7, 2026, 9:20 AM EDT
Not listed Phase 2 Interventional

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Jun 7, 2026, 9:20 AM EDT
Completed No phase listed Observational Results available

Open Label Extension of LipoLat-CS202

NCT02599688
View directory record Official record
Conditions
Glaucoma
Interventions
Observation only
Other
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor

NCT01390779
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Healthy Subjects
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jun 7, 2026, 9:20 AM EDT
Recruiting Not applicable Interventional

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

NCT05924477
View directory record Official record
Conditions
Glaucoma
Interventions
Sulcus tube placement, Anterior chamber (AC) tube placement
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
San Francisco, California • Walnut Creek, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

NCT01711879
View directory record Official record
Conditions
Neovascular Glaucoma
Interventions
Aflibercept
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

NCT03960866
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

NCT01484951
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jun 7, 2026, 9:20 AM EDT
Completed No phase listed Observational

Intra Ocular Pressure During Robotic Prostatectomy

NCT00369057
View directory record Official record
Conditions
Visual Acuity, Visual Disturbance, Intraocular Pressure
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jun 7, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02558400
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jun 7, 2026, 9:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 7, 2026, 9:20 AM EDT